The Experts below are selected from a list of 102 Experts worldwide ranked by ideXlab platform

Fernando Barbosa Noll - One of the best experts on this subject based on the ideXlab platform.

Laura Chavarría - One of the best experts on this subject based on the ideXlab platform.

Radha Y Aras - One of the best experts on this subject based on the ideXlab platform.

  • Projection of burden of cancer mortality for India, 2011-2026.
    Asian Pacific Journal of Cancer Prevention, 2013
    Co-Authors: Ns Murthy, Radha Y Aras
    Abstract:

    Projection of load of cancer mortality helps in quantifying the burden of cancer and is essential for planning cancer control activities. As per our knowledge, there have not been many attempts to project the cancer mortality burden at the country level in India mainly due to lack of data on cancer mortality at the national and state level. This is an attempt to understand the magnitude of cancer mortality problem for the various calendar years from 2011 to 2026 at 5-yearly intervals. Age, sex and site-wise specific cancer mortality data along with Populations covered by the registries were obtained from the report of National Cancer Registry Programme published by Indian Council of Medical Research for the period 2001-2004. Pooled age sex specific cancer mortality rates were obtained by taking weighted average of these six registries with respective registry Populations as weights. The pooled mortality rates were assumed to represent the country’s mortality rates. Populations of the country according to age and sex exposed to the risk of cancer mortality in different calendar years were obtained from the report of Registrar General of India providing Population projections for the country for the years from 2011 to 2026. Population forecasts were combined with the pooled mortality rates to estimate the projected number of cancer mortality cases by age, sex and site of cancer at various 5-yearly periods Viz. 2011, 2016, 2021 and 2026. The projections were carried out for the various cancer-leading sites as well as for ‘all sites’ of cancer. The results revealed that an estimated 0.44 million died due to cancer during the year 2011, while 0.51 million and 0.60 million persons are likely to die from cancer in 2016 and 2021. In the year 2011 male mortality was estimated to be 0.23 million and female mortality to be 0.20 million. The estimated cancer mortality would increase to 0.70 million by the year 2026 as a result of change in size and Composition of Population. In males increase will be to 0.38 millions and in females to 0.32 millions. Among women, cancer of the breast, cervical and ovary account for 34 percent of all cancer deaths. The leading sites of cancer mortality in males are lung, oesophagus, prostrate and stomach. The above results show a need for commitment for tackling cancer by reducing risk factors and strengthening the existing screening and treatment facilities.

Ns Murthy - One of the best experts on this subject based on the ideXlab platform.

  • Projection of burden of cancer mortality for India, 2011-2026.
    Asian Pacific Journal of Cancer Prevention, 2013
    Co-Authors: Ns Murthy, Radha Y Aras
    Abstract:

    Projection of load of cancer mortality helps in quantifying the burden of cancer and is essential for planning cancer control activities. As per our knowledge, there have not been many attempts to project the cancer mortality burden at the country level in India mainly due to lack of data on cancer mortality at the national and state level. This is an attempt to understand the magnitude of cancer mortality problem for the various calendar years from 2011 to 2026 at 5-yearly intervals. Age, sex and site-wise specific cancer mortality data along with Populations covered by the registries were obtained from the report of National Cancer Registry Programme published by Indian Council of Medical Research for the period 2001-2004. Pooled age sex specific cancer mortality rates were obtained by taking weighted average of these six registries with respective registry Populations as weights. The pooled mortality rates were assumed to represent the country’s mortality rates. Populations of the country according to age and sex exposed to the risk of cancer mortality in different calendar years were obtained from the report of Registrar General of India providing Population projections for the country for the years from 2011 to 2026. Population forecasts were combined with the pooled mortality rates to estimate the projected number of cancer mortality cases by age, sex and site of cancer at various 5-yearly periods Viz. 2011, 2016, 2021 and 2026. The projections were carried out for the various cancer-leading sites as well as for ‘all sites’ of cancer. The results revealed that an estimated 0.44 million died due to cancer during the year 2011, while 0.51 million and 0.60 million persons are likely to die from cancer in 2016 and 2021. In the year 2011 male mortality was estimated to be 0.23 million and female mortality to be 0.20 million. The estimated cancer mortality would increase to 0.70 million by the year 2026 as a result of change in size and Composition of Population. In males increase will be to 0.38 millions and in females to 0.32 millions. Among women, cancer of the breast, cervical and ovary account for 34 percent of all cancer deaths. The leading sites of cancer mortality in males are lung, oesophagus, prostrate and stomach. The above results show a need for commitment for tackling cancer by reducing risk factors and strengthening the existing screening and treatment facilities.

Pankaj M. Madhani - One of the best experts on this subject based on the ideXlab platform.

  • Clinical and Contract Research Potential: A Resource Based View (RBV) Approach
    2010
    Co-Authors: Pankaj M. Madhani
    Abstract:

    The purpose of this paper is to discuss the resources that have contributed to the competitive position of the Indian clinical and contract research organizations (CROs). In accordance to resource based view (RBV) approach, the main source of firm's market performance lies on the specific nature of their resources and accumulated competences. A combination of resources including supportive government policies, size and Composition of Population, skilled workforce, sound medical infrastructure, established pharma industry, and global linkages etc. help create a sustainable advantage for the Indian CROs. RBV helps explain the contribution of various resources and capabilities to the Indian CROs.

  • Clinical and Contract Research: Potential
    SCMS Journal of Indian Management, 2010
    Co-Authors: Pankaj M. Madhani
    Abstract:

    The purpose of this paper is to discuss the resources that have contributed to the competitive position of the Indian clinical and contract research organizations (CROs). In accordance to resource based view (RBV) approach, the main source of firm's market performance lies on the specific nature of their resources and accumulated competences. A combination of resources including supportive government policies, size and Composition of Population, skilled workforce, sound medical infrastructure, established pharma industry, and global linkages etc. help create a sustainable advantage for the Indian CROs. RBV helps explain the contribution of various resources and capabilities to the Indian CROs.

  • A Resource Based View (RBV) of Indian Clinical and Contract Research Sector
    2008
    Co-Authors: Pankaj M. Madhani
    Abstract:

    Paper discusses the resources that have contributed to the competitive position of the Indian clinical and contract research sector and analyze the case using the RBV (Resource Based View) of strategy. RBV helps explain the contribution of various resources to the Indian clinical and contract research sector. India is emerging as a natural choice and ultimate destination for contract clinical research services. India’s competitive advantages in clinical trials and contract research are based on favorable regulatory climate, a huge Population with a diversity of diseases, sound infrastructure facilities, lower infrastructure costs, English language proficiency of doctors, staff of hospital, clinical analysts and investigators, large pool of treatment naive patients, high speed of subject recruitment, good patient compliance and retention rate and low cost of clinical studies. Clinical and contract research is a rapidly growing industry in India. Many pharmaceutical organizations and contract research firms have started to extract the vast potential that India has, and are conducting clinical trials and contract research activities in India on a big scale. A combination of resources including supportive government policies, size and Composition of Population, skilled workforce, sound medical infrastructure, established pharma industry, and global linkages etc. help create a sustainable advantage for the Indian clinical and contract research sector. Paper discusses opportunities for Indian clinical and contract research industry, its growth drivers in terms of resources, and emerging challenges.